0000903423-18-000373.txt : 20180703
0000903423-18-000373.hdr.sgml : 20180703
20180703175939
ACCESSION NUMBER: 0000903423-18-000373
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180702
FILED AS OF DATE: 20180703
DATE AS OF CHANGE: 20180703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38550
FILM NUMBER: 18938776
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Translate Bio, Inc.
CENTRAL INDEX KEY: 0001693415
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 611807780
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-945-7361
MAIL ADDRESS:
STREET 1: 29 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: RaNA Therapeutics, Inc.
DATE OF NAME CHANGE: 20161228
4
1
translate.xml
OWNERSHIP DOCUMENT
X0306
4
2018-07-02
1
0001693415
Translate Bio, Inc.
TBIO
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
0
0
1
0
Common Stock
2018-07-02
4
C
0
1674016
A
1674016
I
See Footnote
Common Stock
2018-07-02
4
C
0
1300116
A
2974132
I
See Footnote
Common Stock
2018-07-02
4
C
0
454550
A
3428682
I
See Footnote
Common Stock
2018-07-02
4
P
0
269230
13.00
A
3697912
I
See Footnote
Series A Preferred Stock
2018-07-02
4
C
0
9300000
0
D
Common Stock
1674016
0
I
See Footnote
Series B Preferred Stock
2018-07-02
4
C
0
7222797
0
D
Common Stock
1300116
0
I
See Footnote
Series C Preferred Stock
2018-07-02
4
C
0
2525253
0
D
Common Stock
454550
0
I
See Footnote
S.R. One, Limited acquired 269,230 Common Stock of the Issuer in connection with the Issuer's initial public offering.
The Series A, Series B and Series C Preferred Stock were converted into Common Stock on a 5.5555-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
/s/ Victoria Whyte, Company Secretary, GlaxoSmithKline Plc
2018-07-02